Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP agonist showing up to 20%+ weight loss in trials. Ozempic (semaglutide) remains one of the most proven and accessible options.
Key Differences
- Mechanism: dual vs single receptor
- Weight loss: tirzepatide edges higher on average
- Side effects: similar GI profile
- Cost and coverage vary
Originally published at the source
